Literature DB >> 22011956

Caesarean scar pregnancy: a review of management options.

Katarzyna Litwicka1, Ermanno Greco.   

Abstract

PURPOSE OF REVIEW: The current review aims to provide an overview of the already available and emerging treatment modalities for caesarean scar pregnancy (CSP). RECENT
FINDINGS: CSP is a type of ectopic gestation associated with a high risk of serious complications. The cause of this condition and the best management are still unclear. However, some medical and surgical treatment modalities have been suggested. The main objectives in the clinical management of CSP should be the prevention of massive blood loss and the conservation of the uterus to maintain further fertility, women's health and quality of life. Current data suggest that expectant management should not be recommended, whereas there are accumulating data suggesting that early diagnosis offers single or combined medical and surgical treatment options avoiding uterine rupture and haemorrhage, thus preserving the uterus and fertility.
SUMMARY: No universal treatment guidelines for the management of CSP have been published up to now. The lack of data on the best evidence should encourage any individual case report and further multicentre studies for recommendations establishment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22011956     DOI: 10.1097/GCO.0b013e32834cef0c

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  15 in total

1.  Operative Therapy for Heterotopic Scar Pregnancy and Successful Birth of the Intrauterine Foetus - Case Report and Review of the Literature.

Authors:  R Armbrust; R Krätschell; W Henrich; M David
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

2.  Management of a Viable Cesarean Scar Pregnancy: A Case Report.

Authors:  Mini Mammen Roy; Forough Radfar
Journal:  Oman Med J       Date:  2017-03

3.  Interventions for non-tubal ectopic pregnancy.

Authors:  Ying Long; Huili Zhu; Yuanyuan Hu; Licong Shen; Jing Fu; Wei Huang
Journal:  Cochrane Database Syst Rev       Date:  2020-07-01

4.  Comparative efficacy and safety of local and systemic methotrexate injection in cesarean scar pregnancy.

Authors:  Ping Peng; Ting Gui; Xinyan Liu; Weilin Chen; Zhenzhen Liu
Journal:  Ther Clin Risk Manag       Date:  2015-01-27       Impact factor: 2.423

5.  The value of 3-dimensional color Doppler in predicting intraoperative hemorrhage for cesarean scar pregnancy.

Authors:  Jie Liu; Yiqing Chai; Yang Yu; Liping Liu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

6.  Cesarean scar pregnancy treated by curettage and aspiration guided by laparoscopy.

Authors:  Shan-Rong Shu; Xin Luo; Zhi-Xin Wang; Yu-Hong Yao
Journal:  Ther Clin Risk Manag       Date:  2015-08-03       Impact factor: 2.423

7.  Combined laparoscopy and hysteroscopy vs. uterine curettage in the uterine artery embolization-based management of cesarean scar pregnancy: a retrospective cohort study.

Authors:  Yifeng He; Xin Wu; Qiujing Zhu; Xuezhe Wu; Lingda Feng; Xia Wu; Aimin Zhao; Wen Di
Journal:  BMC Womens Health       Date:  2014-09-24       Impact factor: 2.809

8.  First-trimester diagnosis and management of Cesarean scar pregnancies after in vitro fertilization-embryo transfer: a retrospective clinical analysis of 12 cases.

Authors:  Yan Ouyang; Xihong Li; Yan Yi; Fei Gong; Ge Lin; Guangxiu Lu
Journal:  Reprod Biol Endocrinol       Date:  2015-11-21       Impact factor: 5.211

9.  Novel Medical Therapy of Cesarean Scar Pregnancy With a Viable Embryo Combining Multidose Methotrexate and Mifepristone: A Case Report.

Authors:  Emmanouil Kalampokas; Ioannis Boutas; Konstantinos Panoulis; Theodoros Kalampokas
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

10.  Clinical and ultrasound parameters in prediction of excessive hemorrhage during management of cesarean scar pregnancy.

Authors:  Ting Gui; Ping Peng; Xinyan Liu; Li Jin; Weilin Chen
Journal:  Ther Clin Risk Manag       Date:  2017-06-30       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.